Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017-18 Australian epidemic.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 06 2019
Historique:
received: 14 02 2019
accepted: 06 06 2019
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 28 10 2020
Statut: epublish

Résumé

Human parechovirus type 3 (HPeV3) can cause severe sepsis-like illness in young infants and may be associated with long term neurodevelopmental delay later in childhood. We investigated the molecular epidemiology of HPeV infection in thirty three infants requiring hospitalization before, during and after the peak of the 2017/18 HPeV epidemic wave in Australia. During the peak of the epidemic, all cases were infected with an HPeV3, while before and after the peak, HPeV1 was the predominant type detected. The predominant HPeV3 was the recombinant HPeV3 also detected in the 2013/14 and 2015/16 Australian epidemics. Sepsis-like or meningitis-like symptoms were only reported in cases infected with the recombinant HPeV3. Phylogenetic analysis of the recombinant HPeV3 revealed that the virus continued to evolve, also between the Australian outbreaks, thus indicating continued circulation, despite not being detected and reported in Australia or elsewhere in between epidemic waves. The recombinant HPeV3 continued to show a remarkable stability in its capsid amino acid sequence, further strengthening our previous argument for development of a vaccine or immunotherapeutics to reduce the severity of HPeV3 outbreaks due to this virus.

Identifiants

pubmed: 31222066
doi: 10.1038/s41598-019-45445-z
pii: 10.1038/s41598-019-45445-z
pmc: PMC6586808
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8906

Références

Mol Biol Evol. 1992 Jul;9(4):678-87
pubmed: 1630306
J Mol Evol. 1985;22(2):160-74
pubmed: 3934395
J Clin Virol. 2012 Aug;54(4):337-41
pubmed: 22608363
PLoS Comput Biol. 2019 Apr 8;15(4):e1006650
pubmed: 30958812
J Infect. 2016 Feb;72(2):223-32
pubmed: 26550926
J Gen Virol. 2010 Jan;91(Pt 1):145-54
pubmed: 19759239
Diagn Microbiol Infect Dis. 2010 Oct;68(2):166-73
pubmed: 20846590
Clin Infect Dis. 2010 Feb 1;50(3):357-61
pubmed: 20047496
Sci Rep. 2016 Aug 04;6:30858
pubmed: 27489095
Epidemiol Infect. 2016 Dec;144(16):3451-3460
pubmed: 27571735
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Sci Rep. 2017 Jun 20;7(1):3861
pubmed: 28634337
J Gen Virol. 2010 May;91(Pt 5):1229-38
pubmed: 20089803
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
J Gen Virol. 2004 Feb;85(Pt 2):391-398
pubmed: 14769896
Emerg Infect Dis. 2015 Nov;21(11):1966-72
pubmed: 26485714
J Clin Microbiol. 2008 Sep;46(9):2884-9
pubmed: 18614653
Emerg Infect Dis. 2015 Jul;21(7):1144-52
pubmed: 26082289
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Sci Rep. 2017 Mar 14;7:44423
pubmed: 28290509
PLoS One. 2016 Mar 17;11(3):e0151495
pubmed: 26986479
J Clin Virol. 2018 Jan;98:28-32
pubmed: 29223126
Expert Rev Anti Infect Ther. 2010 Dec;8(12):1417-29
pubmed: 21133666
J Gen Virol. 2007 Mar;88(Pt 3):831-841
pubmed: 17325355
Med J Aust. 2018 May 7;208(8):365-369
pubmed: 29716506
J Clin Virol. 2013 Sep;58(1):188-93
pubmed: 23791478
Pediatr Infect Dis J. 2018 Dec;37(12):1304-1308
pubmed: 30382954
J Paediatr Child Health. 2014 Sep;50(9):746-7
pubmed: 25156711
Mol Biol Evol. 2018 Mar 1;35(3):773-777
pubmed: 29301006
J Clin Virol. 2010 Jul;48(3):202-7
pubmed: 20472496
Eur J Pediatr. 2015 Jul;174(7):919-24
pubmed: 25573462
MMWR Morb Mortal Wkly Rep. 2015 Sep 04;64(34):940-3
pubmed: 26334674
Clin Infect Dis. 2006 Jan 15;42(2):204-10
pubmed: 16355330
PLoS One. 2013 Jul 03;8(7):e68321
pubmed: 23844186
Emerg Infect Dis. 2005 Jan;11(1):103-5
pubmed: 15705330
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
J Paediatr Child Health. 2018 Mar;54(3):289-295
pubmed: 28960646
Comput Appl Biosci. 1992 Jun;8(3):275-82
pubmed: 1633570
Emerg Infect Dis. 2019 Jan;25(1):148-152
pubmed: 30561318

Auteurs

Anthony Chamings (A)

Geelong Centre for Emerging Infectious Diseases, Geelong, Victoria, Australia.
Deakin University, School of Medicine, Geelong, Victoria, Australia.

Julian Druce (J)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, Victoria, Australia.

Leon Caly (L)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, Victoria, Australia.

Yano Yoga (Y)

Victorian Infectious Diseases Reference Laboratory (VIDRL), Doherty Institute, Melbourne, Victoria, Australia.

Philip N Britton (PN)

Marie Bashir Institute, University of Sydney, Sydney, NSW, Australia.
The Children's Hospital at Westmead, Sydney, NSW, Australia.

Kristine K Macartney (KK)

Marie Bashir Institute, University of Sydney, Sydney, NSW, Australia.
The Children's Hospital at Westmead, Sydney, NSW, Australia.
National Centre for Immunisation Research and Surveillance (NCIRS), Sydney, NSW, Australia.

Soren Alexandersen (S)

Geelong Centre for Emerging Infectious Diseases, Geelong, Victoria, Australia. soren.alexandersen@deakin.edu.au.
Deakin University, School of Medicine, Geelong, Victoria, Australia. soren.alexandersen@deakin.edu.au.
Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia. soren.alexandersen@deakin.edu.au.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH